Daily Sepsis Research Analysis
Three noteworthy sepsis studies stood out today: a PROSPERO-registered meta-analysis of RCTs suggests that active management of hyperthermia significantly reduces mortality in adult sepsis; a national cohort analysis delineates clinical/biochemical features that distinguish sepsis-associated liver injury from drug-induced liver injury; and translational immunology work implicates IL-35 in suppressing NK-cell cytotoxicity in septic shock, highlighting a potential therapeutic target.
Summary
Three noteworthy sepsis studies stood out today: a PROSPERO-registered meta-analysis of RCTs suggests that active management of hyperthermia significantly reduces mortality in adult sepsis; a national cohort analysis delineates clinical/biochemical features that distinguish sepsis-associated liver injury from drug-induced liver injury; and translational immunology work implicates IL-35 in suppressing NK-cell cytotoxicity in septic shock, highlighting a potential therapeutic target.
Research Themes
- Active temperature management in adult sepsis
- Diagnostic differentiation of sepsis-associated organ injury
- Cytokine-driven immune dysregulation in septic shock
Selected Articles
1. The Effect of Different Temperature Management Strategies in Adult Sepsis Patients: A Meta-Analysis of Randomized Controlled Trials.
Across eight RCTs (n=1843), active management of hyperthermia significantly reduced mortality in adult sepsis (RR 0.47, 95% CI 0.37–0.59). The review was prospectively registered and used duplicate screening and data extraction.
Impact: Synthesizing randomized evidence, this analysis provides compelling support for active fever management in adult sepsis, a long-debated clinical practice question with direct mortality implications.
Clinical Implications: Consider implementing protocolized active temperature management for hyperthermic adult sepsis patients, with attention to method choice (e.g., external cooling vs. antipyretics), nursing workload, and hemodynamic effects while awaiting further standardization.
Key Findings
- Eight RCTs (n=1843) were included with PROSPERO registration and duplicate study selection.
- Active hyperthermia management reduced mortality in adult sepsis (RR 0.47, 95% CI 0.37–0.59).
- Outcomes included mortality and organ dysfunction; fixed-effect modeling was used.
Methodological Strengths
- Prospective registration (PROSPERO) and duplicate screening/data extraction
- Restriction to randomized controlled trials
Limitations
- Use of a fixed-effect model may not fully account for between-trial heterogeneity
- Abstract lacks detailed risk-of-bias and intervention heterogeneity reporting
Future Directions: Conduct pragmatic, multicenter RCTs comparing standardized temperature thresholds and modalities (external cooling vs. antipyretics), with patient-centered outcomes and safety (e.g., shivering, vasopressor needs).
This investigation seeks to assess the impact of various temperature management approaches on the rates of death and organ failure among adult patients suffering from sepsis. A comprehensive search of PubMed, Embase, and CENTRAL was performed to identify randomized controlled trials (RCTs) published up to September 2024. These trials examined the impact of temperature management strategies on sepsis patients. Two independent investigators conducted literature screening, quality assessment, and data extraction. A meta-analysis was conducted using a fixed-effect model to evaluate outcome measures, including mortality and organ dysfunction. This study is registered with PROSPERO, CRD42024627677. The analysis incorporated eight RCTs, involving 1843 patients. The findings demonstrated that the management of hyperthermia markedly diminished the mortality risk among individuals suffering from sepsis (risk ratio = 0.47, 95% confidence interval [CI]: 0.37-0.59,
2. Identification of Distinguishing Features of Drug-Induced Liver Injury and Liver Injury Associated With Sepsis.
In national cohorts (DILI n=275; SILI n=153), hepatocellular-pattern SILI showed much higher AST peaks (median 1794 IU/L) and rapid normalization (57% normal at 2 weeks) versus DILI (0.9%). Cholestatic/mixed SILI also resolved faster, whereas DILI had higher ALP at onset and higher peak ALT. Mortality was far higher in SILI (30%) than DILI (2%).
Impact: Provides practical, time-sensitive biochemical cues to distinguish SILI from DILI, a frequent and consequential diagnostic dilemma with major therapeutic implications.
Clinical Implications: In suspected sepsis with liver injury, very high AST with rapid improvement (especially hepatocellular pattern) supports SILI over DILI, guiding antimicrobial continuation and avoiding inappropriate drug withdrawals; cholestatic/mixed SILI also tends to resolve quickly.
Key Findings
- Hepatocellular-pattern SILI had markedly higher AST peaks (median 1794 IU/L) than DILI (median 584 IU/L, p<0.001).
- At 2 weeks, 57% of hepatocellular SILI normalized liver tests vs 0.9% of DILI.
- Cholestatic/mixed SILI resolved faster; cholestatic/mixed DILI had higher ALP at onset and higher peak ALT.
- Mortality: SILI 30% vs DILI 2% (p<0.001).
Methodological Strengths
- National, long-term cohorts with explicit diagnostic criteria (RUCAM plus expert opinion for DILI; international consensus for SILI)
- Injury-pattern stratification and analysis of biochemical kinetics
Limitations
- Retrospective design with potential misclassification and confounding
- Single-country cohort may limit external generalizability
Future Directions: Develop and prospectively validate a bedside diagnostic algorithm combining AST magnitude, trajectory, injury pattern, and timing to differentiate SILI from DILI across diverse settings.
BACKGROUND AND AIMS: It can be difficult to distinguish between drug-induced liver injury (DILI) and liver injury associated with sepsis (sepsis induced liver injury, SILI). The aims of the study were to compare clinical and biochemical features between DILI and SILI and identify distinguishing characteristics that might assist in diagnosing these conditions. METHODS: Retrospective cohorts of all DILI cases diagnosed in Iceland 2009-2024 and SILI 2006-2024 were divided into hepatocellular and cholestatic (CS/mixed) patterns. Patients had: > 5× upper limit of normal (ULN) of ALT and/or > 2× ULN in ALP. RUCAM and expert opinion were used in the causality assessment of DILI, and SILI patients had to fulfil international consensus criteria. RESULTS: Overall 275 DILI patients (median age 59 years, 63% females), 153 with SILI (67 years, 49% females) were included. Among patients with HC type, 57% with SILI and only one (0.9%) with DILI had normal liver tests 2 weeks after the event. The peak value of AST was 1794 (IQR 931-3526) IU/L in HC type of SILI but 584 (315-1013) IU/L in DILI, p < 0.001. CS/mixed type of SILI resolved also significantly faster while CS/mixed pattern of DILI had significantly higher ALP at onset and peak ALT than SILI. SILI had 30% mortality compared to DILI (2%) p < 0.001. CONCLUSIONS: Marked elevation of AST and rapid resolution with a HC pattern of liver injury favours the diagnosis of SILI. Cholestatic/mixed SILI also resolves rapidly in contrast to CS/mixed DILI that is associated with markers of more pronounced liver injury.
3. Cytokine Expression and Cytolytic Effect of Natural Killer Cells are Suppressed in Septic Shock.
Septic shock is associated with profound NK-cell dysfunction: reduced activating receptors, cytotoxic granules, degranulation, and cytokine production, especially in non-survivors. Elevated IL-35 correlates with severity and directly suppresses NK-cell activity in vitro, suggesting a mechanistic role.
Impact: Identifies IL-35 as a putative driver of NK-cell suppression in septic shock, bridging clinical immunophenotyping with functional assays and nominating a plausible cytokine target.
Clinical Implications: IL-35-driven NK-cell suppression may contribute to immunoparalysis in septic shock; monitoring IL-35 and NK-cell function could inform immune status, and IL-35 pathway modulation warrants evaluation.
Key Findings
- Activating receptors on NK cells (SLAMF4, NKp30, NKG2D, DNAM-1) were significantly downregulated in septic shock, especially in non-survivors.
- NK cells showed reduced granzyme B/perforin, degranulation, cytokine expression, and cytolytic capacity.
- Serum IL-35 was markedly elevated, positively correlated with disease scores and negatively with NK activating receptors; IL-35 suppressed NK function in vitro.
Methodological Strengths
- Integrated clinical immunophenotyping with functional cytotoxicity assays
- Correlation of cytokine levels (IL-35) with disease severity and cellular markers
Limitations
- Sample size and enrollment details are not specified in the abstract
- Observational design cannot establish causality; no in vivo cytokine blockade data
Future Directions: Validate findings in multicenter cohorts and test IL-35 neutralization or pathway blockade in preclinical sepsis models, followed by early-phase clinical trials with immune-monitoring endpoints.
Septic shock is the most severe stage of sepsis. How immune dysregulation contributes to the pathogenesis of septic shock has not been thoroughly understood. In the current research, the phenotype and function of circulating natural killer (NK) cells of septic patients were characterised. The absolute number of NK cells was comparably reduced in septic shock survivors and non-survivors, probably owing to elevated NK cell apoptosis. Activating receptors including signalling lymphocytic activation molecule 4 (SLAMF4), natural killer cell p30-related protein (NKp30), natural killer group 2, member D (NKG2D), and DNAX accessory molecule 1 (DNAM-1) were significantly downregulated on NK cell surface in septic shock patients, especially non-survivors. Furthermore, the patients' NK cells exhibited lower expression of granzyme B and perforin, weaker target cell-induced degranulation and cytokine expression, as well as incompetent cytolytic effect. These alterations were more profound in septic shock non-survivors. Importantly, serum interleukin-35 (IL-35), which is an immunosuppressive cytokine, was remarkably elevated in septic shock patients. Besides, serum interleukin-35 concentration was positively correlated with disease scores but negatively correlated with NK cell activating receptor expression. In vitro assays indicated IL-35-induced strong suppression of NK cell activity, as evidenced by concomitant downregulation of cytokines and activating receptors along with inhibition of cytolytic capacity. Therefore, we uncovered for the first time the contributing role of IL-35 in septic shock-related human NK cell dysfunction.